Latest Research about Alzheimer’s Disease/Dementia presented by ARIANA PHARMA at the AAIC 2019

Latest Research about Alzheimer’s Disease/Dementia presnted by ARIANA PHARMA at the AAIC 2019

Paris, France and Cambridge,MA – July 25th, 2019 – Ariana Pharma (Paris, France and Cambridge, MA), a leading digital health company focused on developing advanced Artificial Intelligence technologies for patient stratification in clinical trials, today announced that Ariana Pharma work was showcased during three oral presentations.

Following the review published in JPAD [1], including the use of KEM® Artificial Intelligence platform enabling precision medicine development of ANAVEX®2-73, a novel class of orally available selective sigma-1 receptor agonist, ARIANA PHARMA announces that a total of three oral presentations were given at the Alzheimer’s Association International Conference (AAIC) 2019, in Los Angeles from July 14 to 18, 2019. The presentations highlighted novel results from two study cohorts.

Presentation 1 showcased new clinical data identifying gut microbiota biomarkers associated with improved clinical response in patients treated with ANAVEX®2-73. A growing body of evidence identifies gut microbiota as a critical component of healthy brain function, characterized as the ‘gut-brain axis’. High relative abundance of onegut microbiota family and one genus linked to improved responses with ANAVEX®2-73. The effect might potentially be reversal of the microbiota imbalances already documented in Alzheimer’s disease patients and might have a homeostatic effect on the brain-gut-microbiota axis.

DR. Mohamad AFSHAR presenting data identifying gutmicrobiota biomarkers
associated with improved clinical response in patients treated with ANAVEX®2-73

Presentation 2 and 3 displayed results from data-driven KEM® analyses of a well-characterized cohort of subjects having subjective memory complaints (SMC), but not displaying cognitive or memory impairements. KEM® successfully identified genomic biomarkers linked to Alzheimer’s Disease imaging [3] and cognitive tests [4] descriptors used to characterize this cohort. ”We identified an homozygous variant, in a gene involved in the Golgi apparatus, to be significantly linked with change of the resting state activity in the orbito-frontal cortex”. Frédéric Parmentier, PhD, Director Data Science at Ariana Pharma. “I strongly believe that unsupervised and explainable Artificial Intelligence tools are essential to uncover pertinent hypotheses from complex datasets with limited number of fully characterized patients”. KEM® implements an unsupervised and explainable AI approach to uncover pertinent and clinically actionable hypotheses from complex datasets with heterogeneous information.

About Ariana Pharma

Ariana Pharma is a leading digital health Company focused on developing advanced therapeutic decision support systems. Using its KEM® Artificial Intelligence technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and identify best clinical endpoints, best responders and best potential synergistic drugs. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes as well as Real World Evidence data. Combining advanced data analytics with regulatory expertise, Ariana helps translate findings into innovative clinical plans. With a growing number of successful therapeutic development applications, KEM® is the only FDA-reviewed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012. Further information is available at

More information about KEM® framework


[1] B. Vellas ; L.J. Bain ; J. Touchon ; P.S. Aisen (2019): Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018. The Journal of Prevention of Alzheimer’s Disease (JPAD). [PDF][external link]

Presentations details:

Presentation 1 : Exploring Gut Microbiota As a Source of Potential Biomarkers: Initial Results from the Anavex® 2-73 Alzheimer’s Disease Clinical Study [PDF]

Presentation 2 : Combining Omics and Imaging Data from SMC individuals, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease [PDF]

Presentation 3 : Combining Omics and Cognitive Tests Data from SMC individuals, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease [PDF]

Contact Us
2019-07-31T10:00:23+00:00July 29th, 2019|